Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 49Lung Neoplasms 12Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Neoplasm Metastasis 7Multiple Myeloma 6Lymphoma 6Granuloma, Plasma Cell 4Colorectal Neoplasms 4Adenocarcinoma 4Uveal Melanoma 3Neuroblastoma 3Melanoma 3Hematologic Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2ALK-positive NSCLC 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

veliparib 1vandetanib 1pralsetinib 1osimertinib 1cemiplimab 1alectinib 1Vascular Endothelial Growth Factor A 1Temozolomide 1Sorafenib 1Paclitaxel 1Liquid Biopsy 1GSK3352589 1Docetaxel 1Crizotinib 1Carboplatin 1Capecitabine 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 2a × Crizotinib × Clear all
NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡